Andrew Slee
Director de Operaciones en PROTAGENIC THERAPEUTICS, INC. .
Fortuna: - $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Alexander Arrow | M | 53 | 9 años | |
Garo Armen | M | 71 | 30 años | |
Robert Stein | M | 73 | 8 años | |
Brian Corvese | M | 67 | 7 años | |
Khalil Barrage | M | 59 | 17 años | |
Timothy Wright | M | 66 | 2 años | |
Jennifer Buell | M | 50 | 4 años | |
Christina Faragalla | F | - | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Michael G. Chaparian | M | - |
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | - |
Gregory H. Ekizian | M | 60 | 1 años | |
Joshua Silverman | M | 53 | 6 años | |
Robert A. Ziroyan | M | 50 | - | |
Charles R. Cantor | M | 81 |
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | - |
Henry Skinner | M | 60 |
SelectX Pharmaceuticals, Inc.
SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | 1 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 14 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Andrew Slee
- Red Personal